|
|
||||||||
-hydroxysteroid dehydrogenase
,1 Division of Biomedical Sciences, Imperial College School of Medicine, Charing Cross Hospital, London W6 8RF; and 2 Centre for Nephrology, Royal Free and University College Medical School, London W1N 8AA, United Kingdom
To test the proposal that
the enzyme 11
-hydroxysteroid dehydrogenase (11
-HSD) confers
aldosterone specificity on mineralocorticoid receptors in the distal
nephron by inactivating glucocorticoids, we performed a free-flow
micropuncture study of distal tubular function in adrenalectomized rats
infused with high-dose corticosterone. One-half of the rats were
additionally given intravenous carbenoxolone (CBX; 6 mg/h) to inhibit
renal 11
-HSD activity. Although this maneuver lowered fractional
Na+ excretion (1.1 ± 0.2 vs. 1.9 ± 0.2%,
P < 0.01), Na+ reabsorption within the
accessible distal tubule was found to be similar in the two groups of
animals. In contrast, distal tubular K+ secretion was
enhanced in CBX-treated rats: fractional K+ deliveries to
the early and late distal collection sites in the corticosterone-alone
group were 13 ± 1 and 20 ± 3%, respectively (not
significant), whereas corresponding data in the CBX-treated group were
9 ± 1 and 24 ± 2% (P < 0.01). This
stimulation of distal K+ secretion provides the first
direct in vivo evidence that 11
-HSD normally prevents corticosterone
from exerting a mineralocorticoid-like effect in the distal tubule. The
reduction in fractional Na+ excretion during inhibition of
11
-HSD, in the absence of a change in end-distal Na+
delivery, suggests enhanced Na+ reabsorption in the
collecting ducts.
carbenoxolone; sodium reabsorption; potassium secretion; micropuncture; corticosterone
Deceased.
This article has been cited by other articles:
![]() |
S. Tiwari, R. K. Packer, X. Hu, Y. Sugimura, J. G. Verbalis, and C. A. Ecelbarger Increased renal {alpha}-ENaC and NCC abundance and elevated blood pressure are independent of hyperaldosteronism in vasopressin escape Am J Physiol Renal Physiol, July 1, 2006; 291(1): F49 - F57. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. W. Kim, U. K. Schou, C. D. Peters, S. de Seigneux, T.-H. Kwon, M. A. Knepper, T. E.N. Jonassen, J. Froki, and S. Nielsen Increased Apical Targeting of Renal Epithelial Sodium Channel Subunits and Decreased Expression of Type 2 11{beta}-Hydroxysteroid Dehydrogenase in Rats with CCl4-Induced Decompensated Liver Cirrhosis J. Am. Soc. Nephrol., November 1, 2005; 16(11): 3196 - 3210. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Vogt, B. Dick, H.-P. Marti, F. J. Frey, and B. M. Frey Reduced 11{beta}-hydroxysteroid dehydrogenase activity in experimental nephrotic syndrome Nephrol. Dial. Transplant., May 1, 2002; 17(5): 753 - 758. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. R. Nawrocki, C. E. Goldring, R. M. Kostadinova, F. J. Frey, and B. M. Frey In Vivo Footprinting of the Human 11beta -Hydroxysteroid Dehydrogenase Type 2 Promoter. EVIDENCE FOR CELL-SPECIFIC REGULATION BY Sp1 AND Sp3 J. Biol. Chem., April 19, 2002; 277(17): 14647 - 14656. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Serra, D. E. Uehlinger, P. Ferrari, B. Dick, B. M. Frey, F. J. Frey, and B. Vogt Glycyrrhetinic Acid Decreases Plasma Potassium Concentrations in Patients with Anuria J. Am. Soc. Nephrol., January 1, 2002; 13(1): 191 - 196. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |